Ziresovir earns global recognition, boosting hope for young RSV patients and strengthening ArkBio’s innovative pipeline.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

In the newly released 'Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report' by Global ...

The Royal Australian College of GPs (RACGP) has welcomed a new Victorian Government program to provide free respiratory syncytial virus (RSV) vaccines ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

July is Chronic Disease Awareness Month and while many people believe RSV affects only infants and young children, the ...

Public Health – Seattle and King County has seen an increase in emergency visits for COVID-19 over the last month, although ...

As FDA kicked off the drug user fee reauthorization process, Commissioner Marty Makary said he’d like to see lower fees paid ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...